ORMP
Oramed Pharmaceuticals Inc.
$2.47
+$0.13(+5.56%)
18
Overall
--
Value
18
Tech
--
Quality
Market Cap
$93.90M
Volume
109.42K
52W Range
$1.82 - $3.09
Target Price
$3.25
Order:
Income Statement
| Metric | Trend | Chart | 2015 Aug | 2016 Aug | 2017 Aug | 2018 Aug | 2019 Aug | 2020 Aug | 2021 Aug | 2022 Dec | 2023 Dec | 2024 Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| REVENUE | ||||||||||||
| Total Revenue | $2.2M | $641.0K | $2.5M | $2.4M | $2.7M | $2.7M | $2.7M | $2.7M | $1.3M | -- | ||
| Total Revenue | $2.2M | $641.0K | $2.5M | $2.4M | $2.7M | $2.7M | $2.7M | $2.7M | $1.3M | -- | ||
| COST OF GOODS SOLD | ||||||||||||
| Cost of Revenue | -- | $-490.0K | $-187.0K | $86.0K | $-90.0K | -- | -- | -- | -- | -- | ||
| GROSS PROFIT | ||||||||||||
| Gross Profit | $2.2M | $151.0K | $2.3M | $2.5M | $2.6M | $2.7M | $2.7M | $2.7M | $1.3M | -- | ||
| OPERATING EXPENSES | ||||||||||||
| Operating Expenses | $7.4M | $10.2M | $13.0M | $16.1M | $17.2M | $14.5M | $124.0K | $43.3M | $17.4M | $12.8M | ||
| Research & Development | $4.8M | $7.7M | $10.3M | $12.0M | $13.5M | $10.2M | $21.0M | $27.6M | $9.0M | $6.3M | ||
| Research Expense | $4.8M | $7.7M | $10.3M | $12.0M | $13.5M | $10.2M | $21.0M | $27.6M | $9.0M | $6.3M | ||
| Selling, General & Administrative | $2.6M | $2.5M | $2.8M | $4.1M | $3.7M | $4.2M | $5.9M | $13.8M | $8.4M | $6.5M | ||
| Selling & Marketing Expenses | -- | -- | -- | -- | -- | $6.0K | $5.0K | $14.0K | $29.0K | $15.0K | ||
| General & Administrative Expenses | $2.6M | $2.5M | $2.8M | $4.1M | $3.7M | $4.2M | $5.9M | $13.8M | $8.4M | $6.5M | ||
| Salaries & Wages | $-1.3M | $-634.0K | $-1.6M | $-1.5M | $-808.0K | $465.0K | $2.7M | $1.9M | $4.2M | $4.1M | ||
| Depreciation & Amortization | $-4.0K | -- | -- | -- | -- | -- | -- | -- | -- | -- | ||
| Depreciation & Amortization | $-4.0K | -- | -- | -- | -- | -- | -- | -- | -- | -- | ||
| Other Operating Expenses | -- | -- | -- | -- | -- | -- | $124.0K | $264.0K | $267.0K | $265.0K | ||
| OPERATING INCOME | ||||||||||||
| Operating income | $-7.4M | $-10.0M | $-10.8M | $-13.5M | $-14.6M | $-11.8M | $-124.0K | $-40.6M | $-15.8M | $-12.8M | ||
| EBITDA | $-7.2M | $-9.7M | $-10.2M | $-12.8M | $-14.1M | $-11.8M | $-24.1M | $-37.6M | $2.2M | $6.0M | ||
| NON-OPERATING ITEMS | ||||||||||||
| Interest Expense (Non-Operating) | $-6.0K | $-65.0K | $-78.0K | $-67.0K | $-31.0K | -- | $1.0K | -- | $2.0M | $2.6M | ||
| Intinc | -- | -- | -- | -- | -- | -- | -- | $100.0K | $10.0K | -- | ||
| Net Non-Operating Interest Income/Expense | $160.0K | $378.0K | $657.0K | $741.0K | $909.0K | $552.0K | $130.0K | $-3.6M | $8.0M | $4.1M | ||
| Gain on Sale of Securities | $-4.0K | $1.0K | $-1.0K | -- | $-436.0K | $432.0K | $6.0K | $43.0K | -- | -- | ||
| Other Income/Expense | $-150.0K | $-381.0K | $-691.0K | $-800.0K | $-576.0K | $444.0K | $-223.0K | $-630.0K | $-22.9M | $2.3M | ||
| Other Special Charges | $150.0K | $381.0K | $691.0K | $800.0K | $576.0K | $-444.0K | $217.0K | $2.9M | $22.9M | $-2.3M | ||
| SPECIAL ITEMS | ||||||||||||
| Restructring And Mn A Income | $-26.0K | -- | -- | -- | -- | -- | -- | -- | $3.1M | $3.1M | ||
| Special Income Charges | $26.0K | -- | -- | -- | -- | -- | -- | -- | $-3.9M | $-3.1M | ||
| PRE-TAX INCOME | ||||||||||||
| EBIT | $-7.2M | $-9.7M | $-10.2M | $-12.8M | $-14.1M | $-11.8M | $-24.2M | $-37.7M | $2.0M | $5.8M | ||
| Pre-Tax Income | $-7.2M | $-9.6M | $-10.1M | $-12.7M | $-14.1M | $-12.2M | $227.0K | $-37.7M | $5.1M | $-15.9M | ||
| INCOME TAX | ||||||||||||
| Tax Provision | $-1.0K | $1.3M | $400.0K | -- | $300.0K | -- | -- | $100.0K | -- | $3.2M | ||
| NET INCOME | ||||||||||||
| Net Income | $-7.2M | $-11.0M | $-10.5M | $-12.7M | $-14.4M | $-11.5M | $-22.2M | $-36.6M | $5.1M | $-19.1M | ||
| Net Income (Continuing Operations) | $-7.2M | $-11.0M | $-10.5M | $-12.7M | $-14.4M | $-11.5M | $-23.0M | $-37.8M | $5.1M | -- | ||
| Net Income (Discontinued Operations) | $-7.2M | $-11.0M | $-10.5M | $-12.7M | $-14.4M | $-11.5M | $-22.2M | $-36.6M | $5.1M | $-19.1M | ||
| Net Income (Common Stockholders) | $-7.2M | $-11.0M | $-10.5M | $-12.7M | $-14.4M | $11.5M | $-22.2M | $-36.6M | $5.1M | $-19.1M | ||
| Normalized Income | -- | -- | -- | -- | -- | -- | $179.3K | -- | -- | $-12.7M | ||
| TOTALS | ||||||||||||
| Total Expenses | $7.4M | $9.7M | $12.9M | $16.1M | $17.2M | $14.5M | $124.0K | $43.3M | $17.4M | $12.8M | ||
| SHARE & EPS DATA | ||||||||||||
| Average Shares Outstanding | $10.8M | $12.6M | $13.3M | $14.9M | $17.5M | $20.5M | $28.5M | $39.0M | $40.3M | $40.8M | ||
| Average Shares Outstanding (Diluted) | $10.8M | $12.6M | $13.3M | $14.8M | $17.5M | $20.5M | $28.5M | $39.0M | $40.6M | $40.8M | ||
| Shares Outstanding | $11.6M | $13.3M | $14.3M | $17.4M | $17.4M | $23.7M | $38.1M | $39.8M | $41.0M | $41.0M | ||
| Basic EPS | -- | -- | -- | -- | -- | $0.56 | $0.78 | $0.94 | $0.14 | $-0.48 | ||
| Basic EPS (Continuing Operations) | -- | -- | -- | -- | -- | $0.56 | $0.78 | $0.94 | $0.14 | $-0.48 | ||
| Diluted EPS | $0.67 | $0.87 | $0.79 | $0.86 | $0.82 | $0.56 | $0.78 | $0.94 | $0.14 | $-0.48 | ||
| Diluted EPS (Continuing Operations) | -- | -- | -- | -- | -- | -- | -- | $0.94 | $0.14 | $-0.48 | ||
| OTHER METRICS | ||||||||||||
| Commission Expenses | -- | -- | -- | -- | -- | $6.0K | $5.0K | $14.0K | $29.0K | $15.0K | ||
| Earnings from equity interest | -- | -- | -- | -- | -- | -- | -- | -- | $824.0K | -- | ||
| Earnings From Equity Interest Net Of Tax | -- | -- | -- | -- | -- | -- | -- | -- | $824.0K | -- | ||
| Minority Interests | -- | -- | -- | -- | -- | $32.9M | $751.0K | $1.2M | $-437.0K | $-43.0K | ||
| Net Income Extraordinary | -- | -- | -- | -- | -- | -- | -- | $-37.8M | $5.5M | $-19.1M | ||
| Net Income From Other Gains Losses | -- | -- | -- | -- | -- | $690.0K | $1.2M | -- | -- | -- | ||
| Non Recurring Operation Expense | -- | -- | -- | -- | -- | -- | -- | -- | $850.0K | -- | ||
| Other Gand A | $2.6M | $2.5M | $2.8M | $4.1M | $3.7M | $4.2M | $5.9M | $13.8M | $8.4M | $6.5M | ||
| Rent And Landing Fees | $2.6M | $2.5M | $2.8M | $4.1M | $3.7M | -- | -- | -- | -- | -- | ||
| Restruct | $-26.0K | -- | -- | -- | -- | -- | -- | -- | $3.1M | $3.1M | ||
Financial data is updated quarterly and may not reflect the most recent earnings.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | ORMP | $2.47 | +5.6% | 109.42K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Oramed Pharmaceuticals Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW